Femara coated tablets 2.5mg №30

Use - Early stages of invasive breast cancer with hormone receptor-positive cells in postmenopausal women, as adjuvant therapy. - Early stages of invasive breast cancer in postmenopausal women after completing standard adjuvant tamoxifen therapy for 5 years, as extended adjuvant therapy. - Advanced hormone-dependent forms of breast cancer in postmenopausal women (first-line therapy). - How to take - The recommended dose is 2.5 mg once daily, long-term. - For extended adjuvant therapy, treatment should continue for 5 years (not longer than 5 years). - If signs of disease progression appear, letrozole intake should be discontinued. - In the neoadjuvant (preoperative) regimen, letrozole treatment should continue for 4-8 months to achieve optimal tumor size reduction. - If an adequate tumor response to treatment is not achieved, letrozole intake should be discontinued. - Contraindications - Endocrine status characteristic of the reproductive period. - Pregnancy. - Lactation period (breastfeeding). - Children and adolescents under 18 years of age. - Hypersensitivity to letrozole or any other component of the drug. - There is no data on the use of Femara in patients with creatinine clearance less than 10 ml/min. - Storage - The drug should be stored in a dry place, out of reach of children, at a temperature not exceeding 30degreeC. - Shelf life - 5 years. - The drug should not be used after the expiration date.